Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

229 public trials 34 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Active, not recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147

Conditions
Adenocarcinoma Of Esophagus, Digestive System Diseases, Digestive System Neoplasms, +13 more
Locations
  • Hospital de Gastroenterología Dr Bonorino Udaondo Buenos Aires, Argentina
  • Instituto de Investigaciones Metabólicas - IDIM Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires Buenos Aires, Argentina
  • Fundación Centro de Medicina Nuclear y Molecular ER Córdoba, Argentina
View all 227 locations
View Trial Details
Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • University of Alabama - Birmingham ( Site 3061) Birmingham, Alabama, United States
  • University of South Alabama, Mitchell Cancer Institute ( Site 3058) Mobile, Alabama, United States
  • HonorHealth Research Institute - Biltmore ( Site 3043) Phoenix, Arizona, United States
  • Arizona Oncology Associates PC- HOPE ( Site 3049) Tucson, Arizona, United States
View all 231 locations
View Trial Details
Active, not recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

NCT06049212

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Aichi Cancer Center ( Site 0006) Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East ( Site 0002) Kashiwa, Chiba, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 0008) Matsuyama, Ehime, Japan
  • Kanagawa Cancer Center ( Site 0004) Yokohama, Kanagawa, Japan
View Trial Details
Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 6009) Chongqing, Chongqing Municipality, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036) Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • The University of Alabama at Birmingham ( Site 0010) Birmingham, Alabama, United States
  • UC San Diego ( Site 0050) La Jolla, California, United States
  • Cedars Sinai Medical Center ( Site 0027) Los Angeles, California, United States
  • University of California Irvine ( Site 0029) Orange, California, United States
View all 262 locations
View Trial Details
Active, not recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

NCT05382325

Conditions
Advanced or Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Sanford Cancer Center ( Site 0005) Sioux Falls, South Dakota, United States
  • NEXT Oncology ( Site 0001) San Antonio, Texas, United States
  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) Toronto, Ontario, Canada
  • Rambam Health Care Campus-Oncology ( Site 0021) Haifa, Israel
View Trial Details
Active, not recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367

Conditions
Advanced Solid Tumors, Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Northwestern Memorial Hospital ( Site 0002) Chicago, Illinois, United States
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004) Louisville, Kentucky, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) Hackensack, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0005) New Brunswick, New Jersey, United States
View all 25 locations
View Trial Details
Active, not recruiting

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918

Conditions
Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, +1 more
Locations
  • Moores Cancer Center ( Site 1885) La Jolla, California, United States
  • University of Southern California Norris Comprehensive Cancer Center ( Site 1850) Los Angeles, California, United States
  • Hoag Memoriall Hospital Presbyterian ( Site 2056) Newport Beach, California, United States
  • UC Davis Health System ( Site 1864) Sacramento, California, United States
View all 192 locations
View Trial Details
Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358

Conditions
Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, +8 more
Locations
  • University of Alabama at Birmingham-Medicine ( Site 0065) Birmingham, Alabama, United States
  • Arizona Oncology Associates-Arizona Oncology ( Site 0049) Tucson, Arizona, United States
  • Pacific Cancer Care ( Site 0023) Monterey, California, United States
  • UCSF Medical Center at Mission Bay ( Site 0043) San Francisco, California, United States
View all 256 locations
View Trial Details

Related conditions